	US 11,673,957 B2
	Anti-ROR2 antibodies
Cheng Liu, Oakland, CA (US); Su Yan, State College, PA (US); Pei Wang, Union City, CA (US); Nai-Kong Cheung, Purchase, NY (US); Hongfen Guo, Forest Hills, NY (US); and Ming Cheng, Roosevelt Island, NY (US)
Assigned to Eureka Therapeutics, Inc., Emeryville, CA (US)
Appl. No. 15/555,036
Filed by EUREKA THERAPEUTICS, INC., Emeryville, CA (US); and MEMORIAL SLOAN-KETTERING CANCER CENTER, New York, NY (US)
PCT Filed Mar. 10, 2016, PCT No. PCT/IB2016/000255 § 371(c)(1), (2) Date Dec. 27, 2017, PCT Pub. No. WO2016/142768, PCT Pub. Date Sep. 15, 2016.
Claims priority of provisional application 62/219,587, filed on Sep. 16, 2015.
Claims priority of provisional application 62/131,128, filed on Mar. 10, 2015.
Prior Publication US 2018/0127503 A1, May 10, 2018
Int. Cl. C07K 16/18 (2006.01); C07K 16/28 (2006.01); A61K 47/68 (2017.01); C07K 16/22 (2006.01); A61K 39/00 (2006.01)

CPC C07K 16/2857 (2013.01) [A61K 47/6891 (2017.08); C07K 16/22 (2013.01); C07K 16/2803 (2013.01); A61K 2039/505 (2013.01); C07K 2317/21 (2013.01); C07K 2317/31 (2013.01); C07K 2317/34 (2013.01); C07K 2317/622 (2013.01); C07K 2317/732 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01)]

14 Claims

1. A human anti-Receptor Tyrosine Kinase-Like Orphan Receptor 2 (ROR2) antibody, or a functional fragment thereof, wherein the antibody or functional fragment thereof comprises a heavy chain with heavy chain CDRs 1-3 and a light chain with light chain CDRs 1-3, wherein the heavy chain CDRs 1-3 and light chain CDRs 1-3 have the amino acid sequences of SEQ ID NOs:61, 63, 65, 67, 69, and 71, respectively.